How will new high sensitive troponins affect the criteria?

Similar documents
Post-Procedural Myocardial Injury or Infarction

High Sensitivity Troponin Improves Management. But Not Yet

Use of Biomarkers for Detection of Acute Myocardial Infarction

Defining rise and fall of cardiac troponin values

Essam Mahfouz, MD. Professor of Cardiology, Mansoura University

Troponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg

10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better

Peri-operative Troponin Measurements - Pathophysiology and Prognosis

Does serial troponin measurement help identify acute ischemia/ischemic events?

REVISED MI DEFINITIONS IMPLICATIONS FOR CLINICAL TRIALS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands

Post Operative Troponin Leak: David Smyth Christchurch New Zealand

Topic. Updates on Definition of Myocardial Infarction

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU

Troponin when is an assay high sensitive?

TROPONINS HAVE THEY CHANGED YOUR

High-Sensitivity Cardiac Troponin in Suspected ACS

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016

Fifty shades of Troponin. Dr Liam Penny The Queens Hotel, Cheltenham 4 th October 2012

Coding an Acute Myocardial Infarction: Unravelling the Mystery

Acute Coronary Syndrome. Sonny Achtchi, DO

The Universal Definition of Myocardial Infarction 3 rd revision, 2012

Chest pain management. Ruvin Gabriel and Niels van Pelt August 2011

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Fourth Universal Definition of Myocardial Infarction (2018)

BioRemarkable Symposium

Measuring Natriuretic Peptides in Acute Coronary Syndromes

Mario Plebani University-Hospital of Padova, Italy

New universal definition of myocardial infarction

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE

PROMUS Element Experience In AMC

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Chest Pain. Dr Robert Huggett Consultant Cardiologist

The Clinical Laboratory Working with Physicians to Improve Patient Care


Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction

PERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW

Acute Coronary Syndrome

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18

Overall Changes of the Universal Myocardial Infarction Definition

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

Cardiovascular Disease

PERIOPERATIVE EVALUATION AND ANESTHETIC MANAGEMENT OF PATIENTS WITH CARDIAC DISEASE FOR NON CARDIAC SURGERY

Acute coronary syndrome. Dr LM Murray Chemical Pathology Block SA

7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay

High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.

Cardiovascular emergencies. 05/March/2014 László Rudas Szeged

Supplementary Online Content

Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray

FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT

Hit the road Jack! W. FRANK PEACOCK, MD, FACEP, FACC

Myocardial injury, necrosis and infarction

To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome

TROPONIN POSITIVE 2/20/2015 WHAT DOES IT MEAN? When should a troponin level be obtained?

Congreso Nacional del Laboratorio Clínico 2016

Är dagens troponinmetoder tillräckligt känsliga?

In-Ho Chae. Seoul National University College of Medicine

Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)

APPENDIX F: CASE REPORT FORM

BEDSIDE ASSESSMENT OF PATIENTS WITH STEMI

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Objectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?

EDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS

12 Lead EKG Chapter 4 Worksheet

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

hs-c Tn I high sensitivity troponin I <17 min

Current Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN

9/18/2017. Disclosures. Cardiac Troponin: ER Utilization and the Next Generation

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Supplementary Online Content

What is Your Diagnosis?

Value of troponin measurements in carotid artery revascularization

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Acute Coronary Syndrome. Emergency Department Updated Jan. 2017

Acute Myocardial Infarction

Benefit of Performing PCI Based on FFR

ECG in coronary artery disease. By Sura Boonrat Central Chest Institute

Myocardial Infarction In Dr.Yahya Kiwan

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I.

egfr > 50 (n = 13,916)

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Ischemic Heart Disease

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

Supplementary Table 1. Details of the components of the primary composite endpoint

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

CARDIOLOGY GRAND ROUNDS

SUPPLEMENTAL MATERIAL

Impact of Troponin Performance on Patient Care

Belinda Green, Cardiologist, SDHB, 2016

International Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp , September, ISSN:

New diagnostic markers for acute coronary syndromes

Common Codes for ICD-10

Transcription:

How will new high sensitive troponins affect the criteria? Hugo A Katus MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg

Even more sensitive: The new Troponin T assay hs hstnt (5th Generation) 99th percentile = 0.013 µg/l Giannitsis et al Clin Chem 2010

Universal Definition of Myocardial Infarction Criteria of Myocardial Infarction Myocardial necrosis: Detection of rise and/or fall of cardiac biomarker (preferably troponins) with at least one value above the 99th percentile of the upper reference limit With evidence of myocardial ischemia with at least one of the following: Symptoms of ischemia New ST-T changes or LBBB Development of new Q-waves Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality The Joint ESC-ACCF-AHA-WHF Task Force

Sub-Classification of AMI Type 1 Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as plaque erosion or rupture, fissuring or dissection Type 2 Type 3 Myocardial infarction secondary to ischemia due to imbalance between oxygen demand and supply e.g. coronary spasm, anemia, or hypotension Sudden cardiac death with symptoms of ischemia, accompanied by new ST elevation or LBBB, or verified coronary thrombus by angiography or autopsy, but death occurring before blood samples could be obtained Type 4a Myocardial infarction associated with PCI Type 4b Myocardial infarction associated with verified stent thrombosis Type 5 Myocardial infarction associated with CABG

Applying the Universal Definition of MI: What Has Happened with the Diagnosis of Unstable Angina? 100% 90% 80% 70% 130 165 201 259 60% 50% 40% NSTEMI UA STEMI 30% 216 181 145 87 20% 10% 64 64 64 64 0% WHO ctnt 10%CV ctnt 99th hstnt 99th unpublished

Diagnostic performance of serial blood sampling using 99th percentile in evolving MI Higher delta improves specificity Sens % Spec % PPV NPV Baseline sample >99th FU sample 3hours >99th 62 100 77 77 69 65 71 100 FU sample >99th + 20%delta FU sample >99th + 117%delta 85 69 57 100 79 100 67 88 Giannitsis E, et al. Clin Chem 2010

Predictors of Death at 3 years FU N=1530 HR 95%CI p-value TnThs 14 pg/ml 7.591 1.006-57.3 0.049 Age 75 years 2.753 1.448-5.233 0.002 GFR <60 ml/min/1.73m 2 2.318 1.364-3.938 0.002 TIMI Risk Score by Tertiles NT-proBNP > 2399 pg/ml (ROC-optimized) 1.193 0.876-1.626 0.263 5.698 3.252-9.983 <0.001 ctnt 0.03 µg/l 1.752 0.778-3.947 0.176

Unstable angina and treatment options

Sub-Classification of AMI Type 1 Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as plaque erosion or rupture, fissuring or dissection Type 2 Myocardial infarction secondary to ischemia due to imbalance between oxygen demand and supply e.g. coronary spasm, anemia, or hypotension Type 3 Sudden cardiac death with symptoms of ischemia, accompanied by new ST elevation or LBBB, or verified coronary thrombus by angiography or autopsy, but death occurring before blood samples could be obtained Type 4a Myocardial infarction associated with PCI Type 4b Myocardial infarction associated with verified stent thrombosis Type 5 Myocardial infarction associated with CABG

Diagnoses in Chest Pain Patients TnThs negative non-acs 2645 pts (75.6%) CPU Registry Heidelberg (n=3,327) 8.6.2009 30.11.2009 (6-months) TnThs positive non-acs 471 pts (13.5%) STEMI 62 pts (1.8%) NSTEMI 149 pts (4.3%) UA 173 pts (4.9%) Median number of TnThs measurements 3 (IQR 3-5, range 2-6) 20% of consecutive pts admitted to CPU TnThs positive!! 69% elevations are not due to clinical ACS!!

High Sensitive Troponin T is a Strong Predictor of Outcomes in Patients with Chronic Heart Failure - A Study from the Val-HeFT Trial Roberto Latini Heart Failure: Predicting Clinical Outcomes - Monday, November 14, 2005,

Acute Pulmonary Embolism Probability of Long-Term Survival Lankeit M,.Giannitsis E, Katus HA, Konstantinides SDGK 2009; Poster

M-hsTnT (pg/ml) Cardiac CT hstnt and Plaque Morphology in Stable Coronary Artery Disease Normal CA Calcified CA-Pl Non Calcified CA-Pl Complex CA-Pl a. b. c. d. 50 40 30 20 10 0

CT angiography and biomarkers in subjects without ACS as a function of hstnt Characteristic Coronary CT angiography Segments with calcified plaque Segments with non-calcified plaque Segments with mixed plaque Segments with plaque Segments with significant stenosis Vessels with significant stenosis Vessels with plaque Cardiac chamber size and function Left atrial diastolic volume, ml Left atrial systolic volume, ml Left ventricular end diastolic volume, ml Left ventricular end systolic volume, ml Left ventricular mass Left ventricular ejection fraction, % Regional left ventricular dysfunction Biomarkers besides TnT NT-proBNP, pg/ml, median (interquartile range) Cystatin-C, mg/l, median (interquartile range) hstnt 13 pg/ml (N=38) 4.4 (±4.0) 1.8 (±3.0) 1.4 (±2.5) 4.8 (±5.0) 0.4 (±1.0) 0.2 (±0.5) 2 (±1.8) 107 (±33.0) 69 (±31.0) 122 (±45.0) 48 (±41.0) 173 (±60.0) 65 (±14.0) 8 (22%) 248 (92-492) 0.93 (0.75-1.07) hstnt <13 pg/ml (N=302) 1.5 (±3.0) 0.8 (±2.0) 0.5 (±1.4) 1.7 (±3.0) 0.06 (±0.3) 0.05 (±0.3) 0.9 (±1.3) 95 (±24.0) 55 (17.0) 117 (±30.0) 38 (±16.0) 147 (±39.0) 68 (±9.0) 24 (8%) 42 (23-86) 0.82 (0.73-0.92) P <.001.05.04.001.04.09.001.02.01.50.20.01.30.008 <.001.05 Januzzi et al, 2009, Submitted

Sub-Classification of AMI Type 1 Type 2 Type 3 Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as plaque erosion or rupture, fissuring or dissection Myocardial infarction secondary to ischemia due to imbalance between oxygen demand and supply e.g. coronary spasm, anemia, or hypotension Sudden cardiac death with symptoms of ischemia, accompanied by new ST elevation or LBBB, or verified coronary thrombus by angiography or autopsy, but death occurring before blood samples could be obtained Type 4a Myocardial infarction associated with PCI Type 4b Myocardial infarction associated with verified stent thrombosis Type 5 Myocardial infarction associated with CABG

Kaplan-Meier survival estimates for those with (TnT >=0.03) and without (TnT) Prasad, A. et al. J Am Coll Cardiol 2006;48:1765-1770 1,949 patients from the Mayo Clinic registry All had normal CK-MB after the procedure 383 (19.6%) patients with elevated ctnt

Cutoff concentrations for diagnosis of periprocedural MI hstnt ng/l 100 90 80 70 60 0.09 ng/ml 50 40 30 0.03 ng/ml 42 ng/l 20 10 0 3xURL 10%CV =0.03 ng/ml 3xURL 99th perc 4th gen ctnt =0.01 ng/ml 3xURL 99th perc hstnt =14 ng/l

Incidence and prognostic role of Universal Definition Type IV MI Meta-analysis 15 studies, 7578 patients 2359 patients, 4 studies 3x99th percentile Elevation of troponin after scheduled PCI: 28.7% PCI-related MI by Universal definition: 14.5%. <3x99th percentile Type IV MI: Death OR 17.25 (2.71 109.96), P = 0.003, Re-PCI OR 10.86 (3.2 36.94), P<0.001 Testa L et al. QJM 2009;102:369-378

Type 4 MIs after Elective PCI (> 3x 99th percentile = 42 pg/ml) 160 140 120 N=20 paired samples P = 0.0012 100 80 60 40 20 0 Incidence Type IV MI: 10% >3x99th percentile Median 6.13 IQR2.99 to 11.31 TnTbaseline Peak within 24hrs Median 15,8 IQR 9.8 to 23.9

Prognostic significance of preprocedural cardiac troponin elevation among patients with stable CAD undergoing PCI: The EVENT Registry 7592 consecutive patients 142 (6.0%) ctnt + at baseline Jeremias A, et al.circulation 2008

Sub-Classification of AMI Type 1 Type 2 Type 3 Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as plaque erosion or rupture, fissuring or dissection Myocardial infarction secondary to ischemia due to imbalance between oxygen demand and supply e.g. coronary spasm, anemia, or hypotension Sudden cardiac death with symptoms of ischemia, accompanied by new ST elevation or LBBB, or verified coronary thrombus by angiography or autopsy, but death occurring before blood samples could be obtained Type 4a Myocardial infarction associated with PCI Type 4b Myocardial infarction associated with verified stent thrombosis Type 5 Myocardial infarction associated with CABG

CTnT and Out-Come Following CABG- Surgery 100 cumulative cardiac survival [%] 95 90 85 80 ctnt > 0,46µg/L at 48 hrs ctnt > 0,46µg/L at 48 hrs log rank 8.46 p = 0.0036 0 0 200 400 600 800 1000 1200 follow-up [days]

Cutoff concentrations for diagnosis of MI post CABG hstnt ng/l 160 140 120 0.15 ng/ml 100 80 60 40 0.05 ng/ml 70 ng/l 20 0 5xURL 10%CV =0.03 ng/ml 1 2 3 5xURL 99th perc 4th gen ctnt =0.01 ng/ml 5xURL 99th perc hstnt =14 ng/l

Magnitude of ctnt release after CABG postoperative complications 847 consecutive patients Universal MI definition: Type V MI (Periprocedural MI) If ctn >5x99th percentile = 0.07 ng/ml 2% new Q-waves or LBBB 98.9% had a ctnt 0.03 ng/ml, 97.5% had a ctnt 0.10 ng/ml Mohammed, A. A. et al. Circulation 2009;120:843-850

Impact of hstn on AMI Diagnosis/ Criteria Type 1: Many more patients rule in for AMI, prevalence of unstable angina will diminish but risk prediction will be improved Type 2 AMIs will remain a diagnostic challenge Type 4 AMI will be observed in 10-40% of elective PCIs. The prognostic impact of minor marker increases needs to be tested prospectively Type 5 AMI will need revision due to extra-ordinarily high rate of peri-operative AMI diagnoses and lack of prognostic information at low levels

Cardiac Troponin T (µg/l) Troponin Release: Type of Surgery p=0.009 1,6 1,4 1,2 1 0,8 p=0.007 p=0.024 CABG Valve repair CABG + valve miscellaneous 0,6 0,4 0,2 0 4 8 24 48 72 96 time after surgery hours

Short- and long-term biological variation in hsctnt Variable Analytical variation CV A, % * Biological variation CV I, % 48.2 94 CV G, % 85.9 94 Index of Individuality RCV, lognormal increase, % Mean Delta Increase, % Mean Delta Decrease, % Short-term (0-4 h) 53.5 84.5 84.6 58 57.5 Long-term (0-8 weeks) 98 19.6 315 103.4 87

Sensitivity Optimal delta change for prediction of evolving NSTEMI* 100 Sensitivity: 78,6 Specificity: 100,0 Criterion : >242,6287 80 60 40 Sensitivity: 75,0 Specificity: 96,0 Criterion : >117,6546 ROC 0.817 95% CI: 0.655 to 0.924 PPV 91.6 % NPV 86.8 % ROC 0.94 95% CI: 0.812 to 0.990 PPV 100 % NPV 88.9 % 20 0 0 20 40 60 80 100 *MI defined by 4th gen. ctnt 100-Specificity Giannitsis et al. Clin Chem 2010

Sensitivity Maximal hstnt within 6 hours for prediction of MI 100 80 60 Sensitivity: 77,0 Specificity: 88,2 Criterion : >112,4 40 20 0 AUC 0.885 SE 0,0157 Cutoff >112.4 Sens 77.03 (70.7-82.6 ) P<0.0001 Spec 88.16 (85.2-90.7 ) NPV 91.3 (88.6-93.5 ) PPV 70.5 (64.2-76.4 ) 0 20 40 60 80 100 100-Specificity

deltamax_minhstnt Early delta change in ACS versus TnThs-positive non-acs patients 100000 10000 P<0.001 1000 100 10 1 0,1 39% IQR 14.4-139.6 17.3% IQR 8.6-32.6 0,01 ACS N=379 non-acs N=395

number n Diagnostic sensitivity of TnT hs compared to ctnt n = 115 120 100 80 60 40 20 21 21 21 21 20 45 46 55 57 32 31 22 17 17 17 17 STEMI NSTEMI UAP non cardiac 0 ctnt adm hstnt adm ctnt final hstnt final p between ctnt adm and hstnt adm (UAP/NSTEMI) < 0.0001 p between ctnt final and hstnt final (UAP/NSTEMI) < 0.0001 p between ctnt adm and ctnt final (UAP/NSTEMI) = 0.0003 p between hstnt adm and hstnt final (UAP/NSTEMI) = 0.0008

Distribution of new or recurrent MIs (n=1218) by the universal definition of MI clinical classification Morrow, D. A. et al. Circulation 2009;119:2758-2764

All-cause Death by TnThs 99th percentile Survival 1,0 0,9 N=376 N=1530 l 0,8 0,7 N=1154 0,6 0,5 Log rank 33.07 P<0.0001 0,4 0,00 200,00 400,00 600,00 800,00 1000,00 1200,00 days

All-cause mortality at 3yrs follow up ctnths tertiles by diagnosis 25 N=1530 23.8% 20 Tertile1 Median 10.9 (7.3-15.8) 15 9.7% 13.5% 11.9% 18.9% Tertile2 Median 76.1 (50.5-116.5) Tertile3 Median 524 (300.7-1203.8) 10 5.7% 5 0 0.7% 3/420 37/383 47/347 0% 2.9% 0/56 6/106 17/142 1/34 3/21 5/21 Non-STE-ACS STEMI Non-ACS

HsTnT and Outcomes in Heart Failure: The Valheft-Trial Latini R. et al. Circulation 2007;116

Case 4: A 78 year old female History: referred to our chest pain unit with dizziness, vomiting and nausea no typical cardiac chest pain discrete shortness of breath and decrease of performance known diseases: subtle renal failure (MDRD 50 ml/min/1.73m 2 ) CVRF: hypertension, hypercholesterolemia medication: ASS 100mg 0-1-0, candesartan 16mg 1-0-1, hydrochlorothiazid 12,5mg 1-0-1, nebivolol 5mg ½-0-½, pravastatin 20mg 0-0-1, estrogen 0,6mg 1-0-0 Physical examination: 67.0 kg, 1.70 cm, BMI 23 kg/m 2, RR adm 130/60mmHg, HR adm 80/min, 36.1 C Auscultation: Cor/Pulmo: unsuspicious

Case 4: EKG

Case 4: Laboratory Results admission after 24h (norm) creatinine 1.75 1.44 (1.1-1.3) mg/dl urea 100 80 (-45) mg/dl glucose 158 111 (70-110) mg/dl Hb 11.0 10.2 (12-15) g/dl platelets 233 231 (150-440) /nl white blood cells 9.34 7.82 (4-10) /nl C-reactive protein 9.9 8.7 (-5) mg/dl ctnt 0.02 0.04 0.02 (-0,03) µg/l hstnt 40 60 50 30 (-14) pg/ml CK 44 70 (-170) U/l NTproBNP na (-450) ng/l normal values for sodium, potassium, GOT, GPT, LDH

Case 4: Left Ventricular Angiography

Case 4: Coronary Angiography

Postoperative ctnt results as a function of outcome after CABG Mohammed, A. A. et al. Circulation 2009;120:843-850